Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOKE oral semaglutide in early Alzheimer's disease
jRCT2031210108Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Randomised, double-blind trial in Alzheimer's disease (AD) comparing Oral semaglutide OD with Placebo OD (2 arms). Primary endpoint: Change in CDR-SB score. Started Jun 2021; status: active, not recruiting.
02
Drugs
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031210108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210108.